Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.67 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.62 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491473 | 0.89 | CYP17A1 (0.61) | NAMPTCYP17A1PORCNBCL2KDR | |
| SCHEMBL6756707 | 0.86 | NAMPT (0.60) | NAMPTCYP17A1PORCNBCL2RAB9A | |
| SCHEMBL29457342 | 0.84 | NAMPT (0.80) | NAMPTRAB9A | |
| SCHEMBL349933 | 0.84 | NAMPT (0.80) | NAMPTRAB9A | |
| SCHEMBL4759920 | 0.84 | CYP17A1 (0.79) | NAMPTCYP17A1BCL2BECN1PSMB8 | |
| SCHEMBL18570243 | 0.84 | CYP17A1 (0.61) | NAMPTCYP17A1BCL2BECN1PSMB8 | |
| SCHEMBL20865536 | 0.83 | CYP17A1 (0.68) | NAMPTCYP17A1PSMB8MAP4K4KIF11 | |
| SCHEMBL1439714 | 0.83 | NAMPT (0.57) | NAMPTCYP17A1PORCNBCL2RAB9A | |
| SCHEMBL30752011 | 0.83 | NAMPT (0.57) | NAMPTCYP17A1PORCNBCL2RAB9A | |
| SCHEMBL3490522 | 0.83 | NAMPT (0.54) | NAMPTCYP17A1PORCN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | NAMPT 348/4885CYP17A1 517/4885PORCN 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.